138 related articles for article (PubMed ID: 34854108)
21. A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes.
Liu Z; Ding K; Li L; Liu H; Wang Y; Liu C; Fu R
Biomed Pharmacother; 2016 Oct; 83():1032-1037. PubMed ID: 27541047
[TBL] [Abstract][Full Text] [Related]
22. Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer.
Zhang N; Sun P; Jin H; Yang Y; Zhao Q; Zhou L; Guo L; Yang X; Lu L
Anticancer Drugs; 2020 Aug; 31(7):702-708. PubMed ID: 32701251
[TBL] [Abstract][Full Text] [Related]
23. In situ exploring Chidamide, a histone deacetylase inhibitor, induces molecular changes of leukemic T-lymphocyte apoptosis using Raman spectroscopy.
Xie Y; Tang P; Xing X; Zhao Y; Cao S; Liu S; Lu X; Zhong L
Spectrochim Acta A Mol Biomol Spectrosc; 2020 Nov; 241():118669. PubMed ID: 32653824
[TBL] [Abstract][Full Text] [Related]
24. Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model.
Wang SC; Yu CY; Wu YC; Chang YC; Chen SL; Sung WW
Cancer Lett; 2022 Apr; 530():8-15. PubMed ID: 35033588
[TBL] [Abstract][Full Text] [Related]
25. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.
Ji MM; Huang YH; Huang JY; Wang ZF; Fu D; Liu H; Liu F; Leboeuf C; Wang L; Ye J; Lu YM; Janin A; Cheng S; Zhao WL
Haematologica; 2018 Apr; 103(4):679-687. PubMed ID: 29305415
[TBL] [Abstract][Full Text] [Related]
26. The potential efficacy and mechanism of bendamustine in entra-nodal NK/T cell lymphoma.
Gao Y; Feng X; Song W; Li H; Shi C; Jin M; Li Z; Zhang L; Zhang M
Hematol Oncol; 2022 Oct; 40(4):678-688. PubMed ID: 35439335
[TBL] [Abstract][Full Text] [Related]
27. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
[TBL] [Abstract][Full Text] [Related]
28. The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis.
Tonozuka Y; Tanaka H; Nomura K; Sakaguchi K; Soeda J; Kakimoto Y
Cancer Chemother Pharmacol; 2024 Feb; 93(2):137-149. PubMed ID: 37921901
[TBL] [Abstract][Full Text] [Related]
29. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
[TBL] [Abstract][Full Text] [Related]
30. Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B-Cell lymphoma -results of a single center, retrospective cohort in China.
Wang Y; Xue H; Song W; Xiao S; Jing F; Dong T; Wang L
Hematol Oncol; 2022 Oct; 40(4):617-625. PubMed ID: 35165928
[TBL] [Abstract][Full Text] [Related]
31. Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide.
Chen J; Zuo Z; Gao Y; Yao X; Guan P; Wang Y; Li Z; Liu Z; Hong JH; Deng P; Chan JY; Cheah DMZ; Lim J; Chai KXY; Chia BKH; Pang JWL; Koh J; Huang D; He H; Sun Y; Liu L; Liu S; Huang Y; Wang X; You H; Saraf SA; Grigoropoulos NF; Li X; Bei J; Kang T; Lim ST; Teh BT; Huang H; Ong CK; Tan J
Clin Epigenetics; 2023 Feb; 15(1):19. PubMed ID: 36740715
[TBL] [Abstract][Full Text] [Related]
32. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
33. Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy.
Gao S; Li X; Zang J; Xu W; Zhang Y
Anticancer Agents Med Chem; 2017; 17(6):802-812. PubMed ID: 27592546
[TBL] [Abstract][Full Text] [Related]
34. Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells.
Qiao Z; Ren S; Li W; Wang X; He M; Guo Y; Sun L; He Y; Ge Y; Yu Q
Biochem Biophys Res Commun; 2013 Apr; 434(1):95-101. PubMed ID: 23541946
[TBL] [Abstract][Full Text] [Related]
35. Brentuxinmab vedotin, alone or combine with bendamustine in the treatment of natural killer T cell lymphoma.
Zhang P; Shi C; Song Y; Li Z; Zhang M; Jin M
Hematol Oncol; 2022 Dec; 40(5):941-952. PubMed ID: 35797410
[TBL] [Abstract][Full Text] [Related]
36. Chidamide alleviates TGF-β-induced epithelial-mesenchymal transition in lung cancer cell lines.
Lin SH; Wang BY; Lin CH; Chien PJ; Wu YF; Ko JL; Chen JJ
Mol Biol Rep; 2016 Jul; 43(7):687-95. PubMed ID: 27188428
[TBL] [Abstract][Full Text] [Related]
37. Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia.
Kong YL; Pan BH; Liang JH; Zhu HY; Wang L; Xia Y; Wu JZ; Fan L; Li JY; Xu W
Aging (Albany NY); 2020 Aug; 12(16):16083-16098. PubMed ID: 32855355
[TBL] [Abstract][Full Text] [Related]
38. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma.
Que Y; Zhang XL; Liu ZX; Zhao JJ; Pan QZ; Wen XZ; Xiao W; Xu BS; Hong DC; Guo TH; Shen LJ; Fan WJ; Chen HY; Weng DS; Xu HR; Zhou PH; Zhang YZ; Niu XH; Zhang X
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637599
[TBL] [Abstract][Full Text] [Related]
39. Chidamide acts on the histone deacetylase-mediated miR-34a/Bcl-2 axis to regulate NB4 cell line proliferation and apoptosis.
Peng J; Li SJ; Fu X; Liu Y; Zhao XL
Kaohsiung J Med Sci; 2020 Dec; 36(12):1004-1013. PubMed ID: 32783381
[TBL] [Abstract][Full Text] [Related]
40. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells.
Zhou Y; Pan DS; Shan S; Zhu JZ; Zhang K; Yue XP; Nie LP; Wan J; Lu XP; Zhang W; Ning ZQ
Biomed Pharmacother; 2014 May; 68(4):483-91. PubMed ID: 24721323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
